HER2/Neu GP2 vaccine - Greenwich LifeSciences Inc/NuGenerex Immuno-Oncology
Alternative Names: GLSI-100; GP2 peptide + GM-CSF vaccine; GP2 peptide - Greenwich LifeSciences Inc/NuGenerex Immuno-Oncology; HER2/Neu Peptide GP2; HER2/neu peptide vaccineLatest Information Update: 05 Mar 2024
At a glance
- Originator Uniformed Services University of the Health Sciences
- Developer Greenwich LifeSciences Inc; NuGenerex Immuno-Oncology
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III HER2 positive breast cancer
Most Recent Events
- 27 Feb 2024 Phase-III clinical trials in HER2-positive breast cancer(Second-line therapy or greater) in Italy, France, Spain, Germany, Poland (Intradermal) (NCT05232916)
- 22 Feb 2024 Greenwich LifeSciences holds a meeting with EMA for a marketing license application in Europe for GLSI 100
- 14 Feb 2024 Greenwich LifeSciences plans to file a patent protection for manufacturing, pharmacy, or injection processes of HER2/Neu GP2 vaccine